FDA DEVICE FACTS
ZEUS Platform (FG0501US)
iRhythm Technologies, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Zio ECG Utilization Software (ZEUS) Platform is intended to process, store, and analyze electrocardiogram (ECG) recordings captured from a compatible ECG monitor, including automatically detected arrhythmia events and patient-triggered events. The ZEUS Platform also allows for review of the analyzed data and, subsequently, report generation. Interpretation of the analyzed ECG data and the associated diagnosis is the responsibility of the prescribing or treating healthcare professional. The ZEUS Platform is indicated for use on patients 18 years or older who may be asymptomatic or who may suffer from symptoms such as palpitations, shortness of breath, dizziness, light-headedness, pre-syncope, syncope, fatigue, or anxiety. The ZEUS Platform is not intended for detection or notification of hemodynamically unstable or life-threatening arrhythmias or cardiac events requiring urgent medical response. It is not intended for patients at elevated risk of serious cardiovascular events that would require immediate intervention.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。